Elimination of SARS-CoV-2 in nasopharynx and oropharynx after use of an adjuvant gargling and rinsing protocol with an antiseptic mouthwash

Vilhena, Fabiano Vieira; Orcina, Bernardo da Fonseca; Lemos, Lúcio; Less, Jeanette Cecília Fournier; Pinto, Isabella; Santos, Paulo Sérgio da Silva

doi:10.31744/einstein_journal/2021ce6999

Cited by 2 publications

(1 citation statement)

References 5 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ainda, em 4 pacientes que apresentaram ulcerações bucais em conjunto com o Introdução 24 diagnóstico da doença e onde nenhum deles apresentava histórico de ulcerações aftosas ou herpes simples, obteve-se o reparo total das lesões intra-orais entre 12 horas e 4 dias após o início da utilização desse enxaguatório bucal (66). Através do controle de RT-PCR de 4 pacientes com diagnóstico da COVID-19, sendo esses contaminados pela variante P.1 do SARS-CoV-2, houve erradicação total em naso e orafaringe em até 72 horas após o início do enxaguante bucal contendo derivado de ftalocianina (67). É importante salientar que esse enxaguatório bucal participou como coadjuvante terapêutico, não impedindo nem excluindo o tratamento médico necessário.…”

Section: Pseudomonas Aeruginosa Staphylococcus Aureus Salmonella Sp C...unclassified

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Orcina¹

View full text Add to dashboard Cite

Evaluation of the efficacy of an oral antiseptic containing an iron phthalocyanine derivative in improving the clinical picture, decreasing viral load and length of hospital stay in patients with COVID-19The following master's thesis is made up of two scientific articles chosen from the approved research project for this purpose. The first article is a series of 11 patients who were admitted to the hospital and had COVID-19 confirmed by RT-PCR. They were told to use an oral spray containing a phthalocyanine derivative, and the posology was three sprays in each region of the mouth: throat, tongue, and jugal mucosa bilaterally. Still, after spraying, alternate between mouth rinses and gargling for 30 seconds, 5 times per day (after waking up, after breakfast, lunch, dinner and before bed). Furthermore, salivary samples were collected before the patients used the product, as well as 2 and 4 days later, and were tested for SARS-CoV-2 positivity or negativity using RT-PCR. As a result, 48 hours after using the product, 5 patients had negative RT-PCR for salivary samples; 96 hours later, 4 of them had already been discharged from the hospital, and 4 other patients had negative samples. In the second article, a triple-blind randomized clinical trial was conducted with patients who were also COVID-19 positive, as determined by RT-PCR, and were hospitalized. The randomly assigned groups used mouthwash that contained or did not contain the same phthalocyanine derivative and were instructed to rinse/gargle 5 ml of the solution for 1 minute during the same 5 moments mentioned above. The variables studied were length of hospital stay, clinical evolution, need for ICU transfer, and death. To compare the means of age, number of comorbidities, and duration of symptoms prior to hospitalization, the non-parametric Mann-Whitney test was used. The Fisher's exact test was used to assess the need for ICU admission and death. The active group (n=20) and the non-active group (n=21) were formed by randomly assigned patients. The latter had a significantly lower mean age than the experimental group (p=0.0069). Furthermore, the experimental group had a shorter length of stay (p0.05) and did not require ICU referral (p0.05). Despite the lack of statistical significance, the placebo group had three deaths while the active group had none. Thus, these findings suggest that phthalocyanine derivativecontaining mouthwash can be used as a therapeutic adjuvant in patients with COVID-19 who are hospitalized. Finally, the use of phthalocyanine derivative-containing oral spray and mouthwash products does not preclude the use of World Health Organization-established COVID-19 medical protocols (WHO).

show abstract

Section: Pseudomonas Aeruginosa Staphylococcus Aureus Salmonella Sp C...unclassified

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Orcina¹

View full text Add to dashboard Cite

show abstract

Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2

Reia,

da Fonseca Orcina,

Vilhena

et al. 2024

Curr Oral Health Rep

View full text Add to dashboard Cite

Elimination of SARS-CoV-2 in nasopharynx and oropharynx after use of an adjuvant gargling and rinsing protocol with an antiseptic mouthwash

Abstract: in nasopharynx and oropharynx after use of an adjuvant gargling and rinsing protocol with an antiseptic mouthwash [letter]. einstein (São Paulo). 2021;19:eCE6999.

Cited by 2 publications

References 5 publications

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Avaliação da eficácia de um antisséptico oral contendo derivado de ftalocianina de ferro na melhora do quadro clínico, diminuição da carga viral e tempo de internação em pacientes com a COVID-19

Antiviral Mechanism and Clinical Benefits of Mouthwash Active Against SARS-CoV-2

Contact Info

Product

Resources

About